超声引导下的漫射光学断层扫描在预测和监测乳腺癌新辅助化疗中的应用：最新进展
Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.
作者信息
Xu Chen, Vavadi Hamed, Merkulov Alex, Li Hai, Erfanzadeh Mohsen, Mostafa Atahar, Gong Yanping, Salehi Hassan, Tannenbaum Susan, Zhu Quing
机构信息
Department of Electrical and Computer Engineering, University of Connecticut, Storrs, CT, USA Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA.
Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA.
出版信息
Ultrason Imaging. 2016 Jan;38(1):5-18. doi: 10.1177/0161734615580280. Epub 2015 Apr 16.
Abstract
In this manuscript, we review the current progress of utilizing ultrasound-guided diffuse optical tomography (US-guided DOT) for predicting and monitoring neoadjuvant chemotherapy (NAC) outcomes of breast cancer patients. We also report the recent advance on optical tomography systems toward portable and robust clinical use at multiple clinical sites. The first patient who has been closely monitored before NAC, at day 2, day 8, end of first three cycles of NAC, and before surgery is given as an example to demonstrate the potential of US-guided DOT technique.
摘要
在本手稿中，我们回顾了利用超声引导下的漫射光学断层扫描（US-guided DOT）预测和监测乳腺癌患者新辅助化疗（NAC）疗效的当前进展。我们还报告了光学断层扫描系统在多个临床地点实现便携式和稳健临床应用方面的最新进展。以首例在新辅助化疗前、第2天、第8天、新辅助化疗前三个周期结束时以及手术前进行密切监测的患者为例，展示了US-guided DOT技术的潜力。
相似文献
1
Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.
Ultrason Imaging. 2016 Jan;38(1):5-18. doi: 10.1177/0161734615580280. Epub 2015 Apr 16.
2
Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging.
J Biomed Opt. 2018 Oct;24(2):1-9. doi: 10.1117/1.JBO.24.2.021203.
3
Ultrasound and diffuse optical tomography-transformer model for assessing pathological complete response to neoadjuvant chemotherapy in breast cancer.
J Biomed Opt. 2024 Jul;29(7):076007. doi: 10.1117/1.JBO.29.7.076007. Epub 2024 Jul 24.
4
Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization.
Neoplasia. 2008 Oct;10(10):1028-40. doi: 10.1593/neo.08602.
5
Optical tomography with ultrasound localization for breast cancer diagnosis and treatment monitoring.
Surg Oncol Clin N Am. 2007 Apr;16(2):307-21. doi: 10.1016/j.soc.2007.03.008.
6
Correlations Among Ultrasound-Guided Diffuse Optical Tomography, Microvessel Density, and Breast Cancer Prognosis.
J Ultrasound Med. 2018 Apr;37(4):833-842. doi: 10.1002/jum.14416. Epub 2017 Oct 19.
7
US-guided optical tomography: correlation with clinicopathologic variables in breast cancer.
Ultrasound Med Biol. 2013 Feb;39(2):233-40. doi: 10.1016/j.ultrasmedbio.2012.09.014. Epub 2012 Dec 4.
8
A review of optical breast imaging: Multi-modality systems for breast cancer diagnosis.
Eur J Radiol. 2020 Aug;129:109067. doi: 10.1016/j.ejrad.2020.109067. Epub 2020 May 18.
9
Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
Eur J Cancer. 2016 Jan;52:67-76. doi: 10.1016/j.ejca.2015.10.010. Epub 2015 Nov 30.
10
Ultrasound-Guided Diffuse Optical Tomography for Differentiation of Benign and Malignant Breast Lesions: A Meta-analysis.
J Ultrasound Med. 2017 Mar;36(3):485-492. doi: 10.7863/ultra.16.03063. Epub 2017 Jan 29.
引用本文的文献
1
Model-Based Convolution Neural Network for 3D Near-Infrared Spectral Tomography.
IEEE Trans Med Imaging. 2025 May;44(5):2330-2340. doi: 10.1109/TMI.2025.3529621. Epub 2025 May 2.
2
Fundamental effects of array density and modulation frequency on image quality of diffuse optical tomography.
Med Phys. 2025 Feb;52(2):1045-1057. doi: 10.1002/mp.17491. Epub 2024 Nov 4.
3
Monitoring of neoadjuvant chemotherapy through time domain diffuse optics: breast tissue composition changes and collagen discriminative potential.
Biomed Opt Express. 2024 Jul 26;15(8):4842-4858. doi: 10.1364/BOE.527968. eCollection 2024 Aug 1.
4
Deep learning-based fusion of widefield diffuse optical tomography and micro-CT structural priors for accurate 3D reconstructions.
Biomed Opt Express. 2023 Feb 7;14(3):1041-1053. doi: 10.1364/BOE.480091. eCollection 2023 Mar 1.
5
A Narrative Review of Ultrasound Technologies for the Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer.
Cancer Manag Res. 2021 Oct 14;13:7885-7895. doi: 10.2147/CMAR.S331665. eCollection 2021.
6
Machine learning model with physical constraints for diffuse optical tomography.
Biomed Opt Express. 2021 Aug 23;12(9):5720-5735. doi: 10.1364/BOE.432786. eCollection 2021 Sep 1.
7
Deep learning-based method to accurately estimate breast tissue optical properties in the presence of the chest wall.
J Biomed Opt. 2021 Oct;26(10). doi: 10.1117/1.JBO.26.10.106004.
8
Ultrasound segmentation-guided edge artifact reduction in diffuse optical tomography using connected component analysis.
Biomed Opt Express. 2021 Jul 30;12(8):5320-5336. doi: 10.1364/BOE.428107. eCollection 2021 Aug 1.
9
Enhanced diffuse optical tomographic reconstruction using concurrent ultrasound information.
Philos Trans A Math Phys Eng Sci. 2021 Aug 23;379(2204):20200195. doi: 10.1098/rsta.2020.0195. Epub 2021 Jul 5.
10
test-driven upgrade of a time domain multi-wavelength optical mammograph.
Biomed Opt Express. 2021 Jan 27;12(2):1105-1122. doi: 10.1364/BOE.412210. eCollection 2021 Feb 1.
本文引用的文献
1
Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria.
Breast Cancer Res. 2014 Oct 28;16(5):456. doi: 10.1186/s13058-014-0456-0.
2
Predicting breast tumor response to neoadjuvant chemotherapy with diffuse optical spectroscopic tomography prior to treatment.
Clin Cancer Res. 2014 Dec 1;20(23):6006-15. doi: 10.1158/1078-0432.CCR-14-1415. Epub 2014 Oct 7.
3
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33. doi: 10.1007/s00259-014-2739-1. Epub 2014 Mar 20.
4
Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
Clin Cancer Res. 2013 Dec 1;19(23):6360-70. doi: 10.1158/1078-0432.CCR-13-0916.
5
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27. doi: 10.1007/s00259-013-2616-3. Epub 2013 Nov 21.
6
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.
J Oncol. 2013;2013:732047. doi: 10.1155/2013/732047. Epub 2013 Aug 20.
7
Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
Clin Breast Cancer. 2013 Aug;13(4):271-9. doi: 10.1016/j.clbc.2013.02.003. Epub 2013 May 25.
8
Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15.
9
Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy.
Biomed Opt Express. 2013 Jan 1;4(1):105-21. doi: 10.1364/BOE.4.000105. Epub 2012 Dec 14.
10
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Radiology. 2013 Feb;266(2):433-42. doi: 10.1148/radiol.12112415. Epub 2012 Dec 21.
Zotero 插件